Identifying Robust Collateral Sensitivity Phenotypes Exploitable in a Clinical Context to Minimise the Emergence of Antimicrobial Resistance

MRC · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

October 01, 2026
Response Due
Active
Status

Opportunity Overview

T1 Basic Research - T2 Clinical Research

Antimicrobial resistance (AMR) poses a significant threat to global health. Novel strategies in limiting the emergence of AMR are critically needed. One promising approach involves the exploitation of evolutionary biology, specifically a phenomenon known as collateral sensitivity, whereby changes in sensitivity to one class of antibiotics may occur as a result of mutations leading to resistance to an unrelated class of antibiotics. By utilising sequential antibiotic treatment to select against resistance, trade-offs associated with the preservation of antibiotic resistance mutations can be exploited. For a hypersensitive phenotype to be transferable to a clinical setting, it is imperative to establish its reproducibility and conservation across diverse bacterial strains and genetic backgrounds. However, existing studies have predominantly focused on evolving single strains with multiple antibiotics under single growth conditions, leaving a knowledge gap regarding the robustness of collateral sensitivity networks across different strains and conditions. This project aims to address this gap by identifying 1) laboratory media that results in bacteria evolving to resistance along the same evolutionary pathways as we observe in vivo, and 2) robust collateral sensitivity networks reproducible in different strains and genomic backgrounds. Through a comprehensive approach encompassing adaptive laboratory evolution, susceptibility testing, fitness assessment, and detailed bioinformatic analysis, the potential outcomes include the identification of antibiotic pairs that can be sequentially and interchangeably employed to increase bacterial sensitivity to other antibiotics, with a specific focus on carbapenem-resistant, ESBL-producing Enterobacteriaceae. Gaining a more comprehensive understanding of evolutionary trajectories will inform the development of strategies to combat AMR and improve patient outcomes by allowing clinicians to...

This is one of 88 active United Kingdom Healthcare Services opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyMRC
CountryUnited Kingdom
CategoryHealthcare Services
PublishedOctober 02, 2022
Procurement stageActive solicitation
Response dueOctober 01, 2026
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 09, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Related Opportunities in United Kingdom

RFI - Child Digital Health Services
Managed Equipment & Clinical Service Solutions
Clinical Digital Health Solutions 2.0 Framework Agreement
NEYPPC Pharmacy - Unlicensed Manufactured Parenteral Specials
Private Medical Healthcare Trust Scheme
Occupational Health Services (Next Generation)
Outsourced Pharmacy Dispensing Service
Primary Care Healthcare waste collection and disposal service to General Practice and Community Pharmacy for NHS Devon Integrated Care Board (ICB)

See every United Kingdom Healthcare Services opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Healthcare Services intelligence report in your inbox

A personalized report on United Kingdom Healthcare Services opportunities, emailed in 5-10 minutes. One per month, no account needed.